Worldwide, approximately more than 2.8 million people have a diagnosis of MS.

The Middle-East and North Africa (MENA) region had a high prevalence of MS between 1970 and 2015. Iran had the highest prevalence of MS among the countries of the Eastern Mediterranean region (EMR) (72.11/100000). Tehran is the most populous city in Iran, and the capital of this country. The prevalence of MS in Tehran was 79.3 cases per 100000 people in 2006 which increased to 162.38 cases per 100000 people in 2019. The prevalence of MS in north east of Iran ranges between 5.3 to 12.8 per 100000. MS also has a low incidence (2.67 per 100000) and prevalence (13.96 per 100000) in Sistan and Baluchestan, south-east of Iran which is not accurate due to the province’s deprivation of medical centers and the absence of reliable statistics.

With an overall estimated prevalence of 100/100,000 (2022), Iran is among the countries with notable MS prevalence. studies in the field indicate Multiple sclerosis (MS) is one of the most common neurological disorders and is one of the main causes of disability. respectively. There are no systematic and meta-analysis studies on MS in Iran. Therefore, this study was conducted to investigate the prevalence and incidence of MS in Iran using meta-analysis.

In Canada, estimates from individual provinces suggest that the prevalence of MS among Canadians may also be one of the highest in the world. An estimated 93,500 Canadians in private households, and 3,800 in long-term care facilities, have MS. Public Health Agency of Canada also anticipates that number to MS patients rise to 133,635 by 2031 in the country.

In the US, a recently completed prevalence study has estimated that nearly 1 million people live with a diagnosis of MS